Affiliations: [a] Framingham State University, Framingham, MA, USA | [b] Knox College, Galesburg, IL, USA | [c] Loyola University Maryland, Baltimore, MD, USA | [d] University of Massachusetts Lowell, Lowell, MA, USA
Correspondence:
[*]
Correspondence to: Thomas B. Shea, PhD, Department ofBiological Sciences, University of Massachusetts Lowell, Lowell, MA 01854, USA. Tel.: +1 978 934 2881; Fax: +1 978 934 3044; [email protected]
Abstract: Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline performance in CLOX-1. The placebo cohort did not improve in DRS and declined in CLOX-1, but during the open-label extension improved in DRS and ceased declining in CLOX-1. These findings extend prior studies of NF efficacy for individuals without cognitive impairment and with Alzheimer’s disease.
